Home > Our Team > Jeremy DeJournett
Jeremy DeJournett
Chief Technology Officer
Jeremy DeJournett serves as the technical lead and acting Chief Technology Officer for Ideal Medical Technologies. He graduated from the North Carolina School of Science and Mathematics in May 2012, and completed a Bachelor’s of Science in Electrical Engineering from the University of Illinois at Urbana-Champaign in May 2018.

While in school, he worked with a NASA funded CubeSat lab through the Satellite Development Organization, and successfully delivered the CubeSail satellite to Rocket Lab in March of 2018. He was responsible for delivering high level technical reports to principal investigators, as well as translating requirements into technical specifications for the embedded software development team that he led. He streamlined the team’s development process by automating toolchain deployment, centralizing documentation, and increasing developer access to technical knowledge. He also actively recruited for the team, building it from 2 active developers in September 2016 to 15 in May 2018.

In parallel to this work, he was key to the development of Ideal Medical Technologies’ technical stack. During the fall of 2015, he completed the first major revision of the FUSION software, which was used to run a preclinical trial at Wake Forest in December 2015. The following summer, he developed the FUSION simulator, which was used to perform large scale combinatorial analysis of the FUSION software, and to demonstrate the efficacy of the control methodologies in both typical and difficult clinical and non-clinical scenarios.

Through winter of 2016 and spring of 2017, he further extended the FUSION simulator to support other glucose controllers that have seen clinical use, which was used to publish a comparative study of the FUSION controller and reference implementations of the competing controllers. He successfully integrated the FUSION controller with the EIRUS CE marked continuous glucose monitor from Getinge, AB, and tested this working prototype in pre-clinical trials in October 2018. This work included fault tolerance analysis, drug delivery verification, and user interface improvements. He has produced all of the system design and technical documentation required for the Investigational Device Exemption application to the FDA, and will lead the effort in transferring the FUSION devices specifications to the contract manufacturer who will be responsible for creating the commercial grade version of the FUSION device.